ST-193
Based on 4 publication(s) in Google Scholar
ST-193 is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 489416-12-8
- Formula: C24H25N3O
- Molecular Weight:371.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ST-193
More
Biological Activity
IC50: 0.44 nM (Guanarito), 0.62 nM (Junin), 1.4 nM (Lassa) and 3.1 nM (Machupo)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | EC50 |
0.44 nM
Compound: ST-193
|
Antiviral activity against Guanarito virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
Antiviral activity against Guanarito virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23265895] |
| HEK-293T | EC50 |
0.62 nM
Compound: ST-193
|
Antiviral activity against Junin virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
Antiviral activity against Junin virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23265895] |
| HEK-293T | EC50 |
1.4 nM
Compound: ST-193
|
Antiviral activity against Lassa virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
Antiviral activity against Lassa virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23265895] |
| HEK-293T | EC50 |
21 nM
Compound: ST-193
|
Antiviral activity against Sabia virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
Antiviral activity against Sabia virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23265895] |
| HEK-293T | EC50 |
3.1 nM
Compound: ST-193
|
Antiviral activity against Machupo virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
Antiviral activity against Machupo virus pseudovirions infected in HEK293T/17 cells after 72 hrs by luciferase reporter gene assay
|
[PMID: 23265895] |
ST-193 inhibits LASV pseudotypes with an IC50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC50s for Junín, Machupo, Guanarito, and Sabiá were in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 489416-12-8
-
Appearance Solid
-
Molecular Weight 371.47
-
Formula C24H25N3O
-
Color Off-white to pink
-
SMILES
CC(C1=CC=C(CNC2=CC=C3C(N=CN3C4=CC=C(OC)C=C4)=C2)C=C1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
PLoS Pathog
Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane. [Abstract]2022 Aug 15;18(8):e1010625. PMID: 35969633 -
Antiviral Res
2019 Jul:167:68-77. PMID: 30953674 -
Solvent & Solubility
DMSO : 100 mg/mL (269.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Guinea pigs: ST-193 is formulated as a solution in 32% (w/v) 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). Female Hartley guinea pigs are injected intraperitoneally with a 10 mg/mL solution of ST-193 at a volume of either 2.5 mL per kg of body weight (25 mg/kg) or 10 mL per kg (100 mg/kg). Four animals per dose are used, with blood samples collected from two animals per dose at each time point in alternating fashion. Blood samples are obtained at the indicated time points (4-24 h)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burgeson JR, et al. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. [Content Brief]
[2]. Larson RA, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008 Nov;82(21):10768-75. [Content Brief]
[3]. Cashman KA, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011 Apr;90(1):70-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6920 mL | 13.4600 mL | 26.9201 mL | 67.3002 mL |
| 5 mM | 0.5384 mL | 2.6920 mL | 5.3840 mL | 13.4600 mL | |
| 10 mM | 0.2692 mL | 1.3460 mL | 2.6920 mL | 6.7300 mL | |
| 15 mM | 0.1795 mL | 0.8973 mL | 1.7947 mL | 4.4867 mL | |
| 20 mM | 0.1346 mL | 0.6730 mL | 1.3460 mL | 3.3650 mL | |
| 25 mM | 0.1077 mL | 0.5384 mL | 1.0768 mL | 2.6920 mL | |
| 30 mM | 0.0897 mL | 0.4487 mL | 0.8973 mL | 2.2433 mL | |
| 40 mM | 0.0673 mL | 0.3365 mL | 0.6730 mL | 1.6825 mL | |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3460 mL | |
| 60 mM | 0.0449 mL | 0.2243 mL | 0.4487 mL | 1.1217 mL | |
| 80 mM | 0.0337 mL | 0.1683 mL | 0.3365 mL | 0.8413 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6730 mL |
ST-193 Related Classifications
HY-101441 Related Classifications
Powered by Bioz